NEWTOPIA INC - NEWUF STOCK NEWS

On March 7, 2023, Newtopia Inc. (TSXV: NEWU, OTCQB: NEWUF) announced a successful renewal of client contracts from 2022 and completed a non-brokered private placement of units at $0.07 per unit, raising $1.5 million. The funds will support the company's sustainable habit change platform aimed at achieving profitability in 2023. Each unit includes common shares and purchase warrants at prices of CDN$0.10 and CDN$0.15. Contract renewals indicate strong client retention amidst economic challenges, with proven clinical outcomes driving business continuity. Securities are subject to a hold period until July 8, 2023, pending final TSX approvals.

Newtopia Inc. (TSXV: NEWU, OTCQB: NEWUF) announced a successful partnership with Medtronic Canada and Eastern Health aimed at addressing Type 2 diabetes in Newfoundland and Labrador. The pilot program, designed on value-based payment models, targeted nearly 175,000 residents at risk of diabetes. Results showed a weight loss of 3.5% at 6 months and 6.4% at 10 months, with significant A1c reductions among participants. An 81% engagement rate highlighted the program's effectiveness. Following the success, Eastern Health plans to scale the initiative statewide. The program's impact was recognized at the 2022 Diabetes Canada Conference and published in the Canadian Journal of Diabetes.

Newtopia Inc. (NEWUF) announced at the 2022 Diabetes Canada and CSEM Conference the successful outcomes of a trial conducted with Eastern Health aimed at combating diabetes in Newfoundland and Labrador. Approximately 175,000 residents face diabetes risks, and the trial showed that participants experienced an average weight loss of 6.4% over 10 months. Furthermore, A1c levels decreased by 1.1 for participants with high initial levels. With an impressive engagement rate of 81%, Newtopia's approach is proving effective in improving health outcomes through personalized coaching.

Newtopia Inc. reported a 5% sequential revenue growth to $2.7 million in Q3 2022, yet a 9% year-over-year decline. Gross profit margin improved to 55%, up from 50% in Q3 2021. The company achieved record participant engagements of 113,100, a 13% increase year-over-year, and received the highest CDC Full-Plus recognition for its diabetes prevention program. To enhance profitability, Newtopia initiates a cost-cutting program, aiming for $3 to $4 million in annualized savings. A conference call is scheduled for November 8, 2022, to discuss results.

Newtopia Inc. has announced that it will release its financial results for the third quarter and nine months ended September 30, 2022, after market close on November 8, 2022. A conference call will be held on the same day at 5:00 p.m. Eastern Time to discuss these results. Investors can join the call by dialing designated numbers or via a live webcast on the company's investor relations website. Newtopia specializes in creating health platforms that help individuals prevent chronic diseases through personalized programs and data-driven insights.

Newtopia Inc. announced the results of its annual and special meeting of shareholders held on September 14, 2022. All matters presented were approved, including the adoption of the 2022 Option Plan, reserving 23,598,557 common shares for issuance, and the Advance Notice By-law to streamline the nomination process for directors. Both initiatives received conditional approval from the TSX Venture Exchange prior to the meeting. For further details, the company's management information circular dated August 12, 2022, is available on SEDAR.

Newtopia Inc. has achieved the Full-Plus recognition from the CDC for its diabetes prevention program, recognizing its quality and effectiveness in combating type 2 diabetes. This designation highlights Newtopia's commitment to sustainable habit change, contributing to improved health outcomes for participants. With 96 million American adults having prediabetes, the need for effective solutions is critical. Newtopia's personalized platform combines digital technology and human interaction, showing a sustained 0.6% reduction in average A1c levels for participants. This recognition positions Newtopia as a leader in chronic disease prevention.

Newtopia Inc. (TSXV: NEWU, OTCQB: NEWUF) reported Q2 2022 revenue of $2.5 million, steady year-over-year, and a 5% increase in year-to-date revenue to $5.4 million. Participant engagement reached a record 76,000, up 20%. Gross profit margin improved to 47% from 42%. Despite an adjusted operating loss of $1.9 million, the company remains optimistic about a strong second half of 2022, driven by new health plan clients and a recent engagement platform launch aimed at improving efficiencies. A conference call on results is scheduled for August 10, 2022.

Newtopia Inc. (TSXV: NEWU, OTCQB: NEWUF) announced it will release its financial results for Q2 2022 on August 10, 2022, after market close. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss the results in detail. Newtopia provides a tech-enabled health platform aimed at preventing chronic diseases through personalized health programs. The company leverages genetic, social, and behavioral insights to offer individualized prevention strategies, thereby improving health outcomes while reducing healthcare costs.